Inhibrx Share Holder Equity 2020-2022 | INBX

Inhibrx share holder equity from 2020 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Inhibrx Annual Share Holder Equity
(Millions of US $)
2021 $52
2020 $75
2019 $-94
Inhibrx Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $27
2021-12-31 $52
2021-09-30 $28
2021-06-30 $44
2021-03-31 $61
2020-12-31 $75
2020-09-30 $92
2020-06-30 $0
2020-03-31 $0
2019-12-31
2019-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.533B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00